{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T10:02:57Z","timestamp":1774173777910,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Therapeutic apheresis is a term used to describe a group of treatments where blood components are separated in real time, and one component is removed, exchanged, and\/or treated to remove pathogenic substances from the circulation. Plasma exchange, which removed all plasma components, and lipid apheresis which selectively removes lipoproteins from circulation, have both been used to treat atherosclerotic vascular diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>To review the literature regarding the application of therapeutic apheresis for atherosclerotic vascular diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Primarily lipid apheresis is used to treat atherosclerotic vascular diseases, particularly familial hypercholesterolemia, lipoprotein (a) hyperlipoproteinemia and peripheral vascular diseases. Lipid apheresis can be used as first line or second line treatment with a strong evidenced-based recommendation. Its use has decreased atherosclerotic events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSION<\/jats:title>\n                  <jats:p>Lipid apheresis is an important therapy for the treatment of familial hypercholesterolemia, lipoprotein (a) hyperlipoproteinemia and peripheral vascular diseases. Lipid apheresis does more than remove low-density lipoproteins and other lipoproteins but also decreases inflammatory markers and improves blood flow.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpy068","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T06:39:58Z","timestamp":1524206398000},"page":"945-949","source":"Crossref","is-referenced-by-count":6,"title":["Apheresis to Mitigate Atherosclerotic Vascular Disease"],"prefix":"10.1093","volume":"31","author":[{"given":"Bruce S","family":"Sachais","sequence":"first","affiliation":[{"name":"New York Blood Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2270-4821","authenticated-orcid":false,"given":"Beth H","family":"Shaz","sequence":"additional","affiliation":[{"name":"New York Blood Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"2022101717465338500_CIT0001","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the Seventh Special Issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"2022101717465338500_CIT0002","doi-asserted-by":"crossref","first-page":"123S","DOI":"10.1378\/chest.08-0654","article-title":"Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Guyatt","year":"2008","journal-title":"Chest"},{"key":"2022101717465338500_CIT0003","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/MOL.0000000000000234","article-title":"Lipoprotein apheresis: present and future uses","volume":"26","author":"Moriarty","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"2022101717465338500_CIT0004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11883-015-0516-7","article-title":"Lipoprotein apheresis","volume":"17","author":"Bhoj","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"2022101717465338500_CIT0005","doi-asserted-by":"crossref","first-page":"e101290","DOI":"10.1371\/journal.pone.0101290","article-title":"HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia","volume":"9","author":"Zanetti","year":"2014","journal-title":"PLoS One"},{"key":"2022101717465338500_CIT0006","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jca.21413","article-title":"Lipoprotein apheresis reduces circulating galectin-3 in humans","volume":"31","author":"Eliaz","year":"2016","journal-title":"J Clin Apher"},{"key":"2022101717465338500_CIT0007","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/jca.21406","article-title":"Comparison of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia","volume":"31","author":"Drouin-Chartier","year":"2016","journal-title":"J Clin Apher"},{"key":"2022101717465338500_CIT0008","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"key":"2022101717465338500_CIT0009","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0009-3084(94)90152-X","article-title":"Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels","volume":"67-68","author":"Armstrong","year":"1994","journal-title":"Chem Phys Lipids"},{"key":"2022101717465338500_CIT0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1744-9987.2009.00747.x","article-title":"Retrospective analysis of long-term lipid apheresis at a single center","volume":"14","author":"Koziolek","year":"2010","journal-title":"Ther Apher Dial"},{"key":"2022101717465338500_CIT0011","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"2022101717465338500_CIT0012","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"key":"2022101717465338500_CIT0013","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-2004-822989","article-title":"Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program","volume":"4","author":"Leren","year":"2004","journal-title":"Semin Vasc Med"},{"key":"2022101717465338500_CIT0014","first-page":"1667","article-title":"Disorders of lipid metabolism: primary disorders of hyperlipidemia","volume-title":"Williams Textbook of Endocrinology","year":"2003"},{"key":"2022101717465338500_CIT0015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jca.20036","article-title":"Long-term effects of LDL apheresis in patients with severe hypercholesterolemia","volume":"20","author":"Sachais","year":"2005","journal-title":"J Clin Apher"},{"key":"2022101717465338500_CIT0016","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0002-9149(97)00947-8","article-title":"Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group","volume":"81","author":"Gordon","year":"1998","journal-title":"Am J Cardiol"},{"key":"2022101717465338500_CIT0017","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0735-1097(02)01955-1","article-title":"Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART)","volume":"40","author":"Matsuzaki","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2022101717465338500_CIT0018","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.ATV.17.2.239","article-title":"A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants","volume":"17","author":"Wild","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022101717465338500_CIT0019","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"2022101717465338500_CIT0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/aor.12135","article-title":"Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events","volume":"38","author":"Rosada","year":"2014","journal-title":"Artif Organs"},{"key":"2022101717465338500_CIT0021","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"2022101717465338500_CIT0022","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"2022101717465338500_CIT0023","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial","volume":"38","author":"Khan","year":"2017","journal-title":"Eur Heart J"},{"key":"2022101717465338500_CIT0024","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/MOL.0000000000000234","article-title":"Lipoprotein apheresis: present and future uses","volume":"26","author":"Moriarty","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"2022101717465338500_CIT0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1744-9987.2012.01149.x","article-title":"Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney disease","volume":"17","author":"Tamura","year":"2013","journal-title":"Ther Apher Dial"},{"key":"2022101717465338500_CIT0026","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.CIR.95.1.76","article-title":"Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans","volume":"95","author":"Tamai","year":"1997","journal-title":"Circulation"},{"key":"2022101717465338500_CIT0027","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2017-01-757328","article-title":"Demystifying the prothrombotic role of NETs","volume":"129","author":"Schulz","year":"2017","journal-title":"Blood"},{"key":"2022101717465338500_CIT0028","doi-asserted-by":"crossref","first-page":"945","DOI":"10.7326\/0003-4819-125-12-199612150-00001","article-title":"Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease","volume":"125","author":"Kroon","year":"1996","journal-title":"Ann Intern Med"},{"key":"2022101717465338500_CIT0029","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1473-0502(01)00140-9","article-title":"Extracorporeal fibrinogen adsorption\u2013efficacy, selectivity and safety in healthy subjects and patients with foot ulcers","volume":"26","author":"Richter","year":"2002","journal-title":"Transfus Apher Sci"},{"key":"2022101717465338500_CIT0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1525-1594.2002.06880.x","article-title":"RheoSorb: a specific adsorber for fibrinogen elimination in clinical situations with impaired rheology","volume":"26","author":"Koll","year":"2002","journal-title":"Artif Organs"},{"key":"2022101717465338500_CIT0031","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000109101","article-title":"Fibrinogen apheresis in the treatment of peripheral arterial disease","volume":"25","author":"Ramunni","year":"2007","journal-title":"Blood Purif"},{"key":"2022101717465338500_CIT0032","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2006.02.030","article-title":"A systematic review of LDL apheresis in the treatment of cardiovascular disease","volume":"189","author":"Thompsen","year":"2006","journal-title":"Atherosclerosis"},{"key":"2022101717465338500_CIT0033","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jca.21344","article-title":"Selective apheresis of C-reactive protein: a new therapeutic option in myocardial infarction","volume":"30","author":"Sheriff","year":"2015","journal-title":"J Clin Apher"},{"key":"2022101717465338500_CIT0034","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cardiores.2006.03.004","article-title":"C-reactive protein in atherosclerosis: a causal factor","volume":"71","author":"Paffen","year":"2006","journal-title":"Cardiovasc Res"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/31\/8\/945\/46546374\/ajh_31_8_945.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/31\/8\/945\/46546374\/ajh_31_8_945.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T18:57:55Z","timestamp":1666033075000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/31\/8\/945\/5054563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,7,16]]},"published-print":{"date-parts":[[2018,7,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpy068","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,7,16]]}}}